A pharmaceutical company Viking The announcement of a new experimental obesity drug has become one of the most volatile stocks on Wall Street recently. It is an oral tablet that results inOzempicwhich should overcome one of the main drawbacks of current treatments against excess fat mass: the fact that it must be taken by injection.
when bullet After a limited study was declared effective by Viking, the company’s value suddenly increased. However, in the following days, several analysts indicated that, at this point, the company would not have the production capacity to cover the costs of mass production of the drug.
Viking’s new anti-obesity pill.
i obesity week, At the Convention on the Treatment and Prevention of Obesity, which ended on Sunday, November 3, pharmaceutical company Viking Therapeutics presented the results of a study on the new weight-loss pill VK2735. Nine patients who took the highest dose of 100 mg lost within 28 days. 8.2% of your body fatversus 1.4% of those who received placebo.
A study that caused shares of the rush viking, It has become one of the most prominent pharmaceutical companies on the US stock exchange. The new drug comes in the wake of Ozempic, a drug originally made by the Danish company Novo Nordisk for diabetes. Its success was such that it changed the entire Danish economy., But now several competitors, including Viking, are trying to overcome the major problem associated with the drug.
Ozempic In fact, it is still associated with a therapy that requires injections. This complicates long-term recruitment, which must be carried out carefully, and therefore limits its commercial potential. Furthermore, its success has had a devastating effect on its availability to primary patients: diabetics. Creating a pill with similar active ingredients would solve both problems, but some observers aren’t convinced Viking has the tools to market it.
Doubts about Viking’s ability to develop a new tablet
Actually, on Monday Viking shares fell 11 percentAfter some analysis that downplayed Viking’s ability to mass-produce the new pill: “We’re not saying it’s impossible for Viking to make the drug, but we think it’s too expensive. , with the level of investment and expertise that neither Lilly nor Novo has at the moment,” said James Shinn, an analyst Deutsche Bank.
Novo Nordisk is the company that produces Ozempic while Eli Lilly One of Viking’s main competitors in the creation of oral weight loss medicine. Lilly itself is expected to reveal the results of its research on the matter by April 2025. The company believes the oral obesity pill market could reach $150 billion by the beginning of the next decade.
